MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Overview of attention for article published in npj Breast Cancer, January 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#32 of 512)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

So far, Altmetric has seen 6 news stories from 5 outlets.

Source: Novartis Data demonstrate Novartis’ unwavering commitment to reimagining cancer care for patients in the UK in advanced…

As CDK4/6 inhibitors solidify their role as the treatment of choice for patients with hormone receptor–positive, HER2-negative…

BARCELONA -- Abemaciclib (Verzenio) showed benefits in a broader group of breast cancer patients beyond its current indication…

Two cancer drugs have been approved for patients on the NHS in Scotland. An immunotherapy for some people with advanced skin…

News report Two cancer drugs have been approved for patients on the NHS in Scotland.

| NEJM MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer MONARCH 3 final PFS…